Long-term follow-up of pediatric patients exposed to nivolumab + relatlimab fixed-dose combination (FDC) enrolled in the Dutch Melanoma Treatment Registry (DMTR) (CA224-122) First published 13/12/2023 Last updated 20/02/2024 EU PAS number:EUPAS107906 Study Planned